Last updated: February 15, 2026
What Are the Patentability Criteria for Biopharmaceuticals in Latvia?
Latvian patent law aligns with the European Patent Convention (EPC), requiring that biopharmaceutical inventions meet these fundamental conditions:
-
Novelty: The invention must not have been disclosed publicly before the filing date. Prior disclosures include publications, public use, or sales in Latvia or abroad.
-
Inventive Step: The invention must not be obvious to someone skilled in the biopharmaceutical field. This assessment considers the state of the art available up to the filing date.
-
Industrial Applicability: The invention must have practical utility, such as therapeutic or diagnostic use with discernible benefits.
-
Patentable Subject Matter: Latvia excludes certain biological materials and methods from patentability under EPC standards. Specifically, inventions involving human cloning, methods used solely for diagnostic purposes, and certain gene sequences may face restrictions.
How Does Latvia Address Patentability of Biopharmaceuticals?
-
Biological Material: Live biological material can be patentable if claimed suitably. For example, isolated gene sequences and recombinant proteins are patentable if they meet novelty, inventive step, and utility criteria.
-
Diagnostics and Medical Methods: Medical treatment methods are generally excluded from patentability under Article 53(c) EPC. However, specific claim drafting may define isolated compounds or biological materials used in diagnostic assays to overcome exclusions.
-
Gene and Protein Sequences: Isolated gene sequences are patentable provided they are novel, not purely diagnostic, and have industrial utility. Patent claims often cover sequences, methods for producing them, or uses.
What Are the Enforceability Considerations?
-
Authorization and Patenta Rights: Once granted, patents are enforceable for 20 years from filing, subject to fee payments.
-
Third-Party Challenges: Patent validity can be challenged through nullity or opposition proceedings, which Latvia allows up to 9 months after grant. Opposition can question any ground, including lack of novelty or inventive step.
-
Patent Infringement and Litigation: Enforcement occurs through civil courts. Evidence must establish infringement via unauthorized use of the patented biopharmaceutical or process.
-
Data Exclusivity: Data submitted for marketing authorization for new biopharmaceuticals enjoys a period of exclusivity, typically 8 years in the EU, impacting enforcement of identical or similar products.
Scope of Claims in Latvia for Biopharmaceutical Patents
-
Product Claims: Cover isolated compounds, biologics, or biological materials. Proper claim drafting ensures coverage of derivatives, salts, or formulations.
-
Method Claims: Cover methods of production, formulation, or therapeutic use. These are often broad but may be limited by clarity and support requirements.
-
Use Claims: Cover specific therapeutic or diagnostic applications. In Latvia, "second medical use" claims are permissible, following EU norms, with claims such as "use of compound X for treating disease Y."
-
Swiss-Type Claims: Allowed for second medical uses, granted as "use of X for producing a medicament for Y."
-
Claims Strategy: Biopharmaceutical patents often combine multiple types of claims for comprehensive protection, e.g., composition, manufacturing process, and therapeutic application.
Comparison with EU and International Standards
Latvian patentability standards are consistent with the EPC and align with EU regulations concerning biopharmaceutical inventions. Licensing and enforceability mechanisms mirror regional practices, including complex procedural aspects of opposition and nullity.
Key Challenges and Best Practices
-
Clearly Define Biological Material: Use specific sequences, deposit biological material with recognized depositories, and provide detailed description.
-
Avoid EPC Exclusions: For medical methods or diagnostic techniques, frame claims around products or their uses to bypass exclusions.
-
Claim Breadth and Specificity: Balance broad claims with detailed descriptions to maximize scope and enforceability.
-
Monitor Data Exclusivity: Recognize the interplay between patent rights and data exclusivity in regional marketing.
Key Takeaways
-
Latvia’s patent system for biopharmaceuticals follows EPC standards, requiring novelty, inventive step, and industrial utility.
-
Biological material patentability hinges on the material being novel, non-diagnostic, and industrially applicable.
-
Medical methods are typically excluded; claims must focus on compositions, methods of manufacture, or applications.
-
Patent enforcement involves civil litigation, with validity challenges possible within 9 months of grant.
-
Effective claim drafting—covering product, process, and use—maximizes scope and enforceability.
FAQs
1. Can gene sequences be patented in Latvia?
Yes, isolated gene sequences that are novel, have industrial utility, and are not purely diagnostic inventions are patentable.
2. Are medical treatment methods patentable in Latvia?
Generally, no. Medical treatment methods are excluded from patentability under EPC Article 53(c). Claims should focus on compositions or manufacturing methods.
3. How long is patent protection for biopharmaceuticals in Latvia?
20 years from the filing date, subject to annual renewal fees.
4. Can I challenge a patent's validity in Latvia after grant?
Yes, through nullity or opposition proceedings within 9 months post-grant.
5. What strategies help to maximize patent scope?
Using a combination of product claims, process claims, and use claims ensures broader protection and enforcement options.
Sources
[1] European Patent Convention (EPC) guidelines on patentability of biotechnological inventions.
[2] Latvian Patent Law (2018).
[3] Office for Harmonization in the Internal Market (OHIM) guidance on biotech patents.
[4] European Patent Office (EPO) guidelines on patenting biotechnological inventions.
